S0916, MLN1202 in Treating Patients With Bone Metastases

You may be eligible if

• DISEASE CHARACTERISTICS:
• Radiographically documented metastases to the bone by bone scan, x-ray, CT scan, MRI, or PET scan within the past 42 days
• * Documentation of progression of metastatic disease by serial scans is not required for study entry
• No untreated or progressive brain metastases
• * History of brain metastases allowed provided they have been treated and remain controlled
• PATIENT CHARACTERISTICS:
• Zubrod performance status 0-2
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Must consent to urine and blood specimen submissions
• No concurrent uncontrolled illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with the study requirements
• No known hypersensitivity to anti-CCR2 monoclonal antibody MLN1202 or other recombinant human antibodies
• PRIOR CONCURRENT THERAPY:
• At least 14 days since prior radiotherapy and recovered (≤ grade 1 from all related toxicities)
• At least 84 days since prior radionuclide therapy (e.g., strontium, samarium) and recovered (≤ grade 1 from all related toxicities)
• More than 14 days since prior investigational agents, chemotherapeutic agents, or other anticancer agents
• Concurrent bisphosphonate therapy for bone metastases allowed provided treatment was initiated ≥ 28 days before study entry
• * No initiation of bisphosphonates during study treatment
• Concurrent hormonal therapy (e.g., anti-estrogens or anti-androgens) or stable doses of steroids for cancer allowed provided treatment was initiated \> 14 days before study entry
• No concurrent G-CSF or other growth factor support